Use of Thrombolysis in Acute Ischemic Stroke: Analysis of the Nationwide Inpatient Sample 1999 to 2004

Annals of Emergency Medicine

Volumn 50, Issue 2, 2007, Pages 99-107

  Schumacher, H Christian ^a   Bateman, Brian T ^b   Boden Albala, Bernadette ^a   Berman, Mitchell F ^b   Mohr, J P ^a   Sacco, Ralph L ^a,c   Pile Spellman, John ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Columbia University ^*  (United States)

^c New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; CAUCASIAN; CEREBROVASCULAR ACCIDENT; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TEACHING HOSPITAL; UNITED STATES;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 34447521593     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2007.01.021     Document Type: Article

References (56)

1. The National Institute of Neurological Disorders rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587
2. US Food and Drug Administration. Product approval information-licencing action: alteplase (Activase). Available at: http://www.fda.gov/cder/foi/appletter/1996/altegen061896l.pdf. Accessed January 24, 2007.
3. Goldstein L.B. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke 29 (1998) 1602-1604
4. Johnston S.C., Fung L.H., Gillum L.A., et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 32 (2001) 1061-1068
5. Reed S.D., Cramer S.C., Blough D.K., et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32 (2001) 1832-1840
6. Choi J.H., Bateman B.T., Mangla S., et al. Endovascular recanalization therapy in acute ischemic stroke. Stroke 37 (2006) 419-424
7. Lang T.A., and Secic M. Analyzing Multiple Variables. I. Reporting Regression Analyses. How to Report Statistics in Medicine (1997), American College of Physicians, Philadelphia, PA 105-125
8. Field A. Logistic regression. In: Wright D.B. (Ed). Discovering Statistics Using SPSS for Windows (2000), SAGE Publications, Thousand Oaks, CA 163-204
9. Leibson C.L., Naessens J.M., Brown R.D., et al. Accuracy of hospital discharge abstracts for identifying stroke. Stroke 25 (1994) 2348-2355
10. Benesch C., Witter Jr. D.M., Wilder A.L., et al. Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 49 (1997) 660-664
11. Broderick J., Brott T., Kothari R., et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 29 (1998) 415-421
12. Qureshi A.I., Harris-Lane P., Siddiqi F., et al. International classification of diseases and current procedural terminology codes underestimated thrombolytic use for ischemic stroke. J Clin Epidemiol 59 (2006) 856-858
13. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy?. an analysis of patient eligibility. Neurology 56 (2001) 1015-1020
14. Katzan I.L., Hammer M.D., Hixson E.D., et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61 (2004) 346-350
15. Qureshi A.I., Suri M.F., Nasar A., et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery 57 (2005) 647-654
16. Brown D.L., Lisabeth L.D., Garcia N.M., et al. Emergency department evaluation of ischemic stroke and TIA: the BASIC Project. Neurology 63 (2004) 2250-2254
17. Kleindorfer D., Kissela B., Schneider A., et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 35 (2004) e27-e29
18. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 64 (2005) 654-659
19. Deng Y.Z., Reeves M.J., Jacobs B.S., et al. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology 66 (2006) 306-312
20. Katzan I.L., Furlan A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
21. Garcia-Monco J.C., Pinedo A., Escalza I., et al. Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients. Clin Neurol Neurosurg 109 (2007) 50-53
22. Goyal DG, Li J, Mann J, et al. Position statement of the American Academy of Emergency Medicine on the use of intravenous thrombolytic therapy in the treatment of stroke. Available at: http://www.aaem.org/positionstatements/thrombolytictherapy.shtml. Accessed January 24, 2007.
23. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
24. Fagan S.C., Morgenstern L.B., Petitta A., et al., NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50 (1998) 883-890
25. Sandercock P., Berge E., Dennis M., et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35 (2004) 1490-1497
26. Alberts M.J., Latchaw R.E., Selman W.R., et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 36 (2005) 1597-1616
27. Kidwell C.S., Shephard T., Tonn S., et al. Establishment of primary stroke centers: a survey of physician attitudes and hospital resources. Neurology 60 (2003) 1452-1456
28. Heuschmann P.U., Berger K., Misselwitz B., et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34 (2003) 1106-1113
29. Douglas V.C., Tong D.C., Gillum L.A., et al. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke?. Neurology 64 (2005) 422-427
30. Grond M., Stenzel C., Schmulling S., et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29 (1998) 1544-1549
31. Grotta J.C., Burgin W.S., El Mitwalli A., et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58 (2001) 2009-2013
32. Morgenstern L.B., Staub L., Chan W., et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. Stroke 33 (2002) 160-166
33. Lattimore S.U., Chalela J., Davis L., et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke 34 (2003) e55-e57
34. Qureshi A.I., Kirmani J.F., Sayed M.A., et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 64 (2005) 2115-2120
35. Wojner-Alexandrov A.W., Alexandrov A.V., Rodriguez D., et al. Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). Stroke 36 (2005) 1512-1518
36. Merino J.G., Silver B., Wong E., et al. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke 33 (2002) 141-146
37. Vatankhah B., Dittmar M.S., Fehm N.P., et al. Thrombolysis for stroke in the elderly. J Thromb Thrombolysis 20 (2005) 5-10
38. Sylaja P.N., Cote R., Buchan A.M., et al. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 77 (2006) 826-829
39. Link B.G., and Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav (1995) 80-94 Spec No
40. Howard G., Anderson R., Sorlie P., et al. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke 25 (1994) 2120-2125
41. Davey Smith G., Neaton J.D., Wentworth D., et al. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet 351 (1998) 934-939
42. Lynch J., Harper S., Kaplan G.A., et al. Associations between income inequality and mortality among US states: the importance of time period and source of income data. Am J Public Health 95 (2005) 1424-1430
43. Brunner E., Shipley M.J., Blane D., et al. When does cardiovascular risk start?. past and present socioeconomic circumstances and risk factors in adulthood. J Epidemiol Community Health 53 (1999) 757-764
44. Kleindorfer D., Schneider A., and Kissela B.M. The effect of race and gender on patterns of rt-PA use within a population. J Stroke Cerebrovasc Dis 12 (2003) 217-220
45. Wattigney W.A., Croft J.B., Mensah G.A., et al. Establishing data elements for the Paul Coverdell National Acute Stroke Registry: Part 1: proceedings of an expert panel. Stroke 34 (2003) 151-156
46. Arora S., Broderick J.P., Frankel M., et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 36 (2005) 1232-1240
47. Ruland S., Gorelick P.B., Schneck M., et al. Acute stroke care in Illinois: a statewide assessment of diagnostic and treatment capabilities. Stroke 33 (2002) 1334-1339
48. Rymer M.M., and Thrutchley D.E. Organizing regional networks to increase acute stroke intervention. Neurol Res 27 suppl 1 (2005) S9-S16
49. Howard V.J., Acker J., Gomez C.R., et al. An approach to coordinate efforts to reduce the public health burden of stroke: the Delta States Stroke Consortium. Prev Chronic Dis 1 (2004) 1-7
50. Hedworth A.B., and Smith C.S. The Great Lakes Regional Stroke Network experience. Prev Chronic Dis 3 (2006) A128
51. American Stroke Association. Centers for Medicare and Medicaid create new reimbursement category for stroke patients. Stroke news. Available at: http://www.strokeassociation.org/presenter.jhtml?identifier=3032721. Accessed January 24, 2007.
52. Kleindorfer D., Hill M.D., Woo D., et al. A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke 36 (2005) 682-687
53. Silverman I.E., Beland D.K., Bohannon R.W., et al. Expanding the range of therapies for acute ischemic stroke: the early experience of the Regional Stroke Center at Hartford Hospital. Conn Med 68 (2004) 419-429
54. Silver F.L., Rubini F., Black D., et al. Advertising strategies to increase public knowledge of the warning signs of stroke. Stroke 34 (2003) 1965-1968
55. Joint Commission on Accreditation of Healthcare Organizations. Stroke performance implementation guide. Available at: http://www.jointcommission.org/CertificationPrograms/PrimaryStrokeCenter s/implementation_guide.htm. Accessed January 24, 2007.
56. National Stroke Association. Stroke: The First Hours (2005), National Stroke Association, Englewood, CO